265 related articles for article (PubMed ID: 30284393)
1. Postoperative management in cataract surgery: nepafenac and preservative-free diclofenac compared.
Ylinen P; Taipale C; Lindholm JM; Laine I; Holmström E; Tuuminen R
Acta Ophthalmol; 2018 Dec; 96(8):853-859. PubMed ID: 30284393
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory medication following cataract surgery: a randomized trial between preservative-free dexamethasone, diclofenac and their combination.
Ylinen P; Holmström E; Laine I; Lindholm JM; Tuuminen R
Acta Ophthalmol; 2018 Aug; 96(5):486-493. PubMed ID: 29369527
[TBL] [Abstract][Full Text] [Related]
3. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo.
McCafferty S; Harris A; Kew C; Kassm T; Lane L; Levine J; Raven M
BMC Ophthalmol; 2017 Feb; 17(1):16. PubMed ID: 28219426
[TBL] [Abstract][Full Text] [Related]
4. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery.
Miyake K; Ota I; Miyake G; Numaga J
J Cataract Refract Surg; 2011 Sep; 37(9):1581-8. PubMed ID: 21855758
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial.
Campa C; Salsini G; Perri P
Curr Eye Res; 2018 Mar; 43(3):362-367. PubMed ID: 29120255
[TBL] [Abstract][Full Text] [Related]
6. Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac.
Danni R; Viljanen A; Aaronson A; Tuuminen R
Acta Ophthalmol; 2019 Sep; 97(6):589-595. PubMed ID: 30620140
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
Almeida DR; Khan Z; Xing L; Bakar SN; Rahim K; Urton T; El-Defrawy SR
J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
[TBL] [Abstract][Full Text] [Related]
8. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ
Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Tolerability of Diclofenac and Nepafenac.
Achiron A; Karmona L; Mimouni M; Gershoni A; Dzhanov Y; Gur Z; Burgansky Z
J Ocul Pharmacol Ther; 2016 Nov; 32(9):601-605. PubMed ID: 27513223
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory Medication of Cataract Surgery in Pseudoexfoliation Syndrome - NSAID Is Needed.
Ilveskoski L; Taipale C; Tuuminen R
Curr Eye Res; 2020 Jul; 45(7):814-819. PubMed ID: 31801388
[TBL] [Abstract][Full Text] [Related]
11. Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification.
Tzelikis PF; Morato CS; Neves NT; Hida WT; Alves MR
J Cataract Refract Surg; 2018 Apr; 44(4):440-446. PubMed ID: 29685777
[TBL] [Abstract][Full Text] [Related]
12. Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects.
Cagini C; Cerquaglia A; Pellegrino A; Iannone A; Lupidi M; Fiore T
Acta Ophthalmol; 2021 Feb; 99(1):e70-e73. PubMed ID: 32558305
[TBL] [Abstract][Full Text] [Related]
13. Topical nonsteroidal anti-inflammatory drugs as adjuvant therapy in the prevention of macular edema after cataract surgery.
Cardascia N; Palmisano C; Centoducati T; Alessio G
Int Ophthalmol; 2017 Oct; 37(5):1127-1131. PubMed ID: 27766540
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
[TBL] [Abstract][Full Text] [Related]
15. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.
Warren KA; Fox JE
Retina; 2008; 28(10):1427-34. PubMed ID: 18664937
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac.
Sengupta S; Vasavada D; Pan U; Sindal M
Indian J Ophthalmol; 2018 Jun; 66(6):827-830. PubMed ID: 29785993
[TBL] [Abstract][Full Text] [Related]
17. The Comparative Efficacy and Tolerability of Diclofenac 0.1% and Bromfenac 0.09% Ophthalmic Solutions after Cataract Surgery.
Giannaccare G; Finzi A; Sebastiani S; Greco F; Versura P; Campos EC
Curr Eye Res; 2018 Dec; 43(12):1445-1453. PubMed ID: 30009640
[TBL] [Abstract][Full Text] [Related]
18. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema.
Mathys KC; Cohen KL
Eye (Lond); 2010 Jan; 24(1):90-6. PubMed ID: 19229275
[TBL] [Abstract][Full Text] [Related]
19. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery.
Zaczek A; Artzen D; Laurell CG; Stenevi U; Montan P
J Cataract Refract Surg; 2014 Sep; 40(9):1498-505. PubMed ID: 25135542
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Subtenon Triamcinolone Acetonide Injection with Topical Nepafenac for the Treatment of Pseudophakic Cystoid Macular Edema.
Yüksel B; Uzunel UD; Kerci SG; Sağban L; Küsbeci T; Örsel T
Ocul Immunol Inflamm; 2017 Aug; 25(4):513-519. PubMed ID: 27015572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
